Supernus, Inc. (INDV) stock
INDVNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SUPN
$35.37+0.12 (+0.34%)
Close on Oct 30, 2026Market cap $4.17BP/E 9.9Yield –
Supernus EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Supernus's EPS for the twelve months ending Sep 30, 2026 was $3.57, up 253.5% year over year. For fiscal 2025 it was $1.64, up 3180.0% from the year before.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.64 | +3180.0% |
| FY2024 | Dec 31, 2024 | $0.05 | – |
| FY2023 | Dec 31, 2023 | -$0.92 | – |
| FY2022 | Dec 31, 2022 | -$0.30 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.12 | +239.4% |
| Q2 FY2026 | Jun 30, 2026 | $0.98 | +600.0% |
| Q1 FY2026 | Mar 31, 2026 | $0.69 | +81.6% |
| Q4 FY2025 | Dec 31, 2025 | $0.78 | +387.5% |
| Q3 FY2025 | Sep 30, 2025 | $0.33 | +106.3% |
| Q2 FY2025 | Jun 30, 2025 | $0.14 | – |
| Q1 FY2025 | Mar 31, 2025 | $0.38 | -15.6% |
| Q4 FY2024 | Dec 31, 2024 | $0.16 | – |
| Q3 FY2024 | Sep 30, 2024 | $0.16 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.72 | – |
| Q1 FY2024 | Mar 31, 2024 | $0.45 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?